2007
DOI: 10.1016/j.jconrel.2006.12.030
|View full text |Cite
|
Sign up to set email alerts
|

A type of esophageal stent coating composed of one 5-fluorouracil-containing EVA layer and one drug-free protective layer: In vitro release, permeation and mechanical properties

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
47
0
1

Year Published

2009
2009
2017
2017

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 57 publications
(48 citation statements)
references
References 23 publications
0
47
0
1
Order By: Relevance
“…Bronchotracheal stent coatings need to have proper flexibility to resist the rigors of compression and elongation required for deployment of the stent and subsequent peristaltic movements in situ (Guo et al, 2007). The tensible testing gives an indication of the strength and elasticity of the coating.…”
Section: Mechanical Properties Of the Pu Constructsmentioning
confidence: 99%
“…Bronchotracheal stent coatings need to have proper flexibility to resist the rigors of compression and elongation required for deployment of the stent and subsequent peristaltic movements in situ (Guo et al, 2007). The tensible testing gives an indication of the strength and elasticity of the coating.…”
Section: Mechanical Properties Of the Pu Constructsmentioning
confidence: 99%
“…Effort has been directed toward suppressing the expansion of hyperplasia by covering the stent with polymeric film or membrane. The stent covering material should have a proper mechanical properties such as elasticity to accommodate the expansion required for the stent placed in a tortuous part of the vessel or tract, and toughness that could resist the rigors of compression to make the profile of the stent as small as possible so that it could be loaded into a delivery catheter with smallest diameter [46]. Minimal profile of the stent and delivery catheter is preferred so that they can be delivered through an endoscope as shown in Figure 3.…”
Section: Non-vascular Stentsmentioning
confidence: 99%
“…The drug-loaded stents and control stents were prepared in our lab as follows: the drug-loaded layer was prepared by fully blending 5-FU particles and melted EVA in various ratios and then compressing the blends into films with a heat source. 25 In brief, 50 g EVA was added into the chamber of HAAKE Rheocord System (Rheocord 90, HAAKE Mess-Technic GmbH, Karlsruhe, Germany) and heated until it was completely melted. Afterward, the micronized 5-FU was added slowly into the melted EVA at the weight ratios of 20/80, 40/60, and 60/40 (5-FU/EVA), and then blended at 958C for 2 h by stirring at 37 rpm.…”
Section: Fabrication Of Drug-loaded Stentsmentioning
confidence: 99%
“…In our previous study, 25,26 we developed a type of esophageal stent coating, which consists of one 5-FUcontaining ethylene-vinyl acetate (EVA) layer and one drug-free EVA protective layer. In the present study, we fabricate and evaluate in vivo a drug-loaded stent which is a combination of a self-expandable commercial nitinol stent and the above coating.…”
Section: Introductionmentioning
confidence: 99%